Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-IMMUNE: Durvalumab + EC in Neoadjuvant Breast Cancer
NCT03356860Phase 2Completed
- Sponsor
- Grand Hôpital de Charleroi
- Start
- Apr 2017
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in breast cancer (2 arms), sponsored by Grand Hôpital de Charleroi. Primary endpoints: Adverse events at 74 weeks and Pathological response at 24 weeks. Started Apr 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03356860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356860.